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Background: Quality of life (QoL) is increasingly recognized as a critical outcome parameter in mental health
studies. The aim of this study was to investigate different domains of the QoL in persons with obsessive-compulsive
disorder (OCD) before and after a multimodal, disorder-specific in- and outpatient treatment.
Methods: Data of 73 persons with OCD treated in an inpatient setting followed by outpatient treatment were
analyzed. The World Health Organization Quality of Life abbreviated (a multidimensional measure of the QoL) and
the Beck Depression Inventory were administered prior to (baseline) and 12 months after the inpatient treatment
(follow-up).
Results: At baseline, participants reported a significantly diminished psychological, social, physical, and global QoL
compared to the German general population. Environmental QoL was not impaired in the present sample. The QoL
was significantly improved at follow-up, except for social QoL, but remained below norm values. The QoL
improvement was predicted by improvements of depressive symptoms.
Conclusions: The results indicate that persons with OCD suffer from a very low QoL. The QoL was significantly
improved after 12 months of intensive state-of-the-art treatment. However, the QoL indices remained considerably
lower than population norm values, indicating the need for additional research into novel treatment options for
persons with OCD.
Keywords: Obsessive-compulsive disorder, Quality of life, Cognitive behavioral therapy, Exposure, Inpatient,
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Obsessive-compulsive disorder (OCD) is a prevalent
mental disorder with a lifetime prevalence of 2% to 3%
[1,2]. OCD is characterized by recurrent intrusive
thoughts or impulses (obsessions) and repetitive be-
havioral or mental acts (compulsions). The disorder
frequently takes a chronic course [3]. Cognitive behav-
ioral therapy (CBT) including exposure and response
prevention (EX/RP) is the most effective treatment for
persons with OCD [4,5]. To date, research into treat-
ment efficacy has largely focused on the effects at the* Correspondence: elisabeth.hertenstein@uniklinik-freiburg.de
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distribution, and reproduction in any mediumsymptom level, with the main outcome parameters
being the reduction of obsessive/compulsive or depres-
sive symptoms. In addition, the quality of life (QoL)
has increasingly been recognized as an important but
rather under-investigated outcome component [6,7].
QoL has been conceptualized by the World Health
Organization (WHO) as ‘a multidimensional construct
describing an individual’s subjective perception of their
position in life in the context of the culture and value
system in which they live, and in relation to their goals,
expectations, standards, and concerns’ (The WHOQOL
Group, 1996).
Research on the QoL is important for a number of rea-
sons: First, information on the domains of QoL that are
particularly impaired in persons with distinct disordersntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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aspects. Furthermore, advanced knowledge about particu-
lar symptoms that have a high impact on the QoL might
enable us to tailor the treatment to these symptoms [8].
Finally, QoL research might help to explain the frequently
observed discrepancy between clinical symptom ratings
and patients’ overall ratings of the treatment effects.
A diminished QoL in persons with OCD compared to
population norms has been demonstrated by a number
of studies, [7,9]. However, QoL impairments in persons
with OCD have not yet been well understood with
respect to different QoL domains and the association
between QoL and psychiatric symptoms [10]. This
aspect is further complicated by the use of different QoL
measures which depict different domains of the QoL.
Improvements of the QoL in persons with OCD have
been described after CBT with EX/RP in several uncon-
trolled pre- and post-treatment studies [6,7,9,11,12] and
one randomized controlled trial with a waiting-list con-
trol group [13]. Cordioli et al. [13] observed a significant
improvement of the psychological, physical, social, and
environmental QoL after CBT in a group format, but
not after a waiting period. The therapeutic gains were
maintained at 3 months follow-up. Diefenbach et al. [11]
assessed the QoL in 70 outpatients with OCD before
and directly after individual CBT and reported signifi-
cant improvements of work, social and family func-
tioning with large effect sizes. Norberg et al. [7] found a
substantial impairment in the QoL before treatment.
One subgroup showed a substantial improvement dir-
ectly after CBT with EX/RP along with a reduction in
OCD symptoms. In contrast, a second subgroup also
demonstrated reductions in the severity of OCD symp-
toms but no QoL improvement, and a third subgroup
did not improve on either measure. Stewart et al. [12]
analyzed data of 403 persons with severe OCD and a
high rate of comorbid disorders who had not responded
to previous treatments. The authors observed a signifi-
cant QoL improvement directly after an intensive resi-
dential treatment with daily CBT sessions in their
sample. Concerning pharmacological treatment without
CBT, statistically significant but small QoL improve-
ments have been observed after treatment with either
venlafaxine or paroxetine for 12 weeks [14]. Hollander
et al. [10] reported that escitalopram and paroxetine
were significantly superior to placebo in improving the
QoL in most domains of the SF-36. However, another
randomized placebo-controlled study by Koran et al.
[15] found that fluvoxamine was not superior to placebo
in improving the QoL.
Interestingly, QoL improvements in persons with
OCD appear to be relatively independent from the
reduction of OC symptoms [14]. Some studies have
indicated that the severity of comorbid depressivesymptoms might be more relevant than the severity of
OCD symptoms [9,16].
Until now, research into potential changes in the QoL
in persons with OCD after psychotherapy has largely
been limited to short-term outcomes. We found only
two psychotherapy studies which provide data on the
QoL at follow-up time points: Mawson et al. [17] de-
monstrated long-term effects (114 weeks) of a combined
treatment (selective serotonin reuptake inhibitor (SSRI)
and EX/RP) on a social adjustment scale, and Cordioli
[13] reported that the effects of their cognitive behav-
ioral group therapy on QoL remained stable over a
period of 3 months. This situation has led several
authors to recommend additional research on long-term
changes of the QoL based on psychometrically sound
measures [7,9,11]. Research in persons with other
disorders suggests that the QoL can be improved on a
long-term basis. For instance, QoL improvements over a
period of 12 months have been demonstrated in persons
with social phobia [18] and depression [19].
The aim of our data analysis was to investigate the QoL
of persons with OCD prior to and 12 months after an in-
tense multimodal inpatient treatment based on CBT (aver-
aging 9 weeks) and subsequent outpatient treatment.
Particularly, we addressed the following research ques-
tions: (1) Do persons with OCD suffer from a diminished
QoL compared to population norms? (2) Do they exhibit
an improved QoL 12 months after treatment? (3) If so, are
the QoL scores comparable to population norms after
treatment? (4) How are QoL changes over a 1-year period
related to changes in depressive symptoms?
Methods
Sample
The current study included patients with a primary diag-
nosis of OCD according to International Classification
of Diseases 10 (ICD-10) criteria who had been treated
for OCD at the University Medical Center Freiburg be-
tween July 2005 and March 2010 and who had com-
pleted a measure of QoL at baseline and at follow-up.
Exclusion criteria were a primary diagnosis other than
OCD, a diagnosis of psychosis or organic brain disorder,
and an inpatient stay shorter than 1 week. We chose to
include a wide range of patients because we aimed to
depict the QoL of inpatients with OCD, who typically
suffer from comorbid disorders and who are often
prescribed psychotropic medication.
Of a total sample of 235 inpatients with OCD in this
period, 73 fulfilled the criteria described above and were
included into the present analysis. The mean age of the
analyzed sample was 36 years (standard deviation 11.7
years); 39 participants (53%) were female. The participants
had been suffering from OCD for an average of 15 years.
Diagnoses were established by experienced clinicians
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participant flow and the study design are presented in
Figure 1. Demographic and clinical data of the analyzed
sample and the excluded patients at baseline can be found
in Tables 1 and 2.
Beck Depression Inventory (BDI) scores at baseline
and at discharge for the analyzed sample (n = 73) did
not significantly differ from the scores of the n = 162
persons who were excluded due to missing QoL data
(p > 0.05 for both comparisons). Baseline scores of
the Symptom Checklist 90 (SCL-90-R) and the Global
Assessment of Functioning (GAF) were also comparable
(p > 0.05 for all subscales). The samples were similar
concerning gender and education.
Study design
All participants gave written informed consent for the
use of their data for scientific purposes. The study de-
sign is outlined in Figure 1. Data were collected within
the framework of the routine quality assurance of the
hospital at three time points: baseline, discharge, and
follow-up 12 months after discharge.
Measures
Quality of life
The main outcome of this study was the QoL as assessed
by the World Health Organization Quality of Life
abbreviated (WHOQoL-BREF). The WHOQoL-BREF is an=235 
treated for OCD at the University 
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Figure 1 Study design and participant flow. BDI, Beck Depression Inven
disorder; QoL, quality of life; WHOQOL-BREF, World Health Organization Qucross-culturally valid instrument with good to excellent
psychometric properties [20]. The internal consistency of
the German version of the instrument is strong, with
Cronbach’s α between 0.76 and 0.88 for the different
subscales [21]. A field study on the psychometric proper-
ties of the German instrument showed that subjects from
the general population scored highest and psychiatric
patients scored lowest on all subscales, demonstrating
the construct validity of the questionnaire [21]. The
WHOQoL-BREF is a short version of the WHOQoL-100
and covers four facets of the QoL, namely physical,
psychological, social, and environmental QoL, in addition
to a global measure. The physical QoL scale contains
among others questions about physical pain, sleep, and
the ability to move, whereas psychological QoL includes
self-acceptance and unpleasant feelings such as sadness
and anxiety. Social QoL is about relationships and social
support, and environmental QoL includes questions about
the housing situation, financial situation, and access to in-
formation. The questionnaire consists of 26 items which
are rated on a 5-point Likert scale. For each domain of the
instrument, a final score ranging from 0 (very poor QoL)
to 100 (excellent QoL) can be calculated with the help of a
formula provided by Angermeyer et al. [21].
Depression
Depressive symptoms were measured by the BDI II [22].
The BDI is a widely used self-rated instrument with goodcluded: n=162 
missing QoL data: n=155 
diagnosis of psychosis: n=2 
diagnosis of organic disorder: n=3 
duration of stay shorter than one week: n=2 
tory II; n, total number of subjects; OCD, obsessive-compulsive
ality of Life abbreviated.
Table 1 Baseline sociodemographic and clinical data I
Included (n = 73)
n (%)
Excluded (n = 162)
n (%)
Gender
Female 39 (53) 90 (56)
Male 34 (47) 72 (44)
Social status
Unmarried 46 (63) 117 (72)
Married 21 (29) 27 (17)
Cohabiting 4 (5) 8 (5)
Other 2 (3) 10 (6)
Occupational status
Employed 34 (47) 49 (30)
Student 14 (19) 29 (18)
Unemployed 9 (12) 32 (20)
Retired 8 (11) 28 (17)
Other 2 (3) 24 (15)
School qualification
None 2 (3) 4 (2)
Hauptschulea 18 (25) 31 (19)
Realschulea 27 (37) 64 (40)
Abitura 26 (35) 55 (34)
Occupational qualification
None (learned) 18 (25) 41 (25)
Apprenticeship 40 (55) 83 (51)
Polytechnic 2 (3) 9 (6)




60 (82) 140 (86)
(F42.2)
Mainly obsessions 7 (10) 8 (5)
(F42.0)
Mainly compulsions 6 (8) 11 (7)
(F42.1)
Comorbid diagnosesb
Substance dependence 3 (4) 12 (7)
Mood disorder 19 (26) 53 (33)
Anxiety disorders 3 (4) 6 (4)
Eating disorders 2 (3) 2 (1)
Attention deficit
hyperactivity disorder
1 (1) 4 (2)
Tourette’s syndrome 3 (4) 3 (2)
Personality disorder 2 (3) 10 (6)
Organic brain disorder - 3 (2)
Table 1 Baseline sociodemographic and clinical data I
(Continued)
Psychosis - 2 (1)
Bipolar disorder - 2 (1)
Somatoform disorder - 3 (2)
n, total number of subjects. aGerman Hauptschule comprises 9 years of formal
education, Realschule 10 years, and Abitur (A levels) 13 years. bComorbid
diagnoses refer to the baseline assessment time point, not lifetime diagnoses.
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with the number of threshold symptoms as assessed by
the Structural Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), demonstrating the questionnaire’s construct
validity [22]. The same study also demonstrated a strong in-
ternal consistency (α = 0.92) and a high test-retest reliability
(r = .96). BDI scores ≤ 13 can be interpreted as no or min-
imal depression, scores from 14 to 19 indicate mild depres-
sion, and scores ≥ 29 indicate severe depression [23].
Psychological distress
In order to characterize the sample, the SCL-90-R [24]
was applied at baseline to assess participants’ level of
psychological symptoms and psychological distress. The
DSM-IV axis V GAF scale was administered as a clin-
ician rating of global functioning, with functioning
scores ranging from 1 to 100 (excellent functioning).
Intervention
All study participants received an inpatient, multi-
modal, disorder-specific treatment program. The main
treatment component was CBT with in vivo EX/RP.
Treatment was carried out by experienced cognitive
behavioral therapists following a structured concept
[25]. The concept included extensive assessment andTable 2 Baseline sociodemographic and clinical data II
Included (n = 73)
mean ± SD
Excluded (n = 168)
mean ± SD
p
Age 35.5 ± 11.7 33.7 ± 11.1 0.26
Duration of OCD
(years)
15.3 ± 11.9 15.4 ± 12.0 0.95
Age at onset of
OCD
20.7 ± 11.9 19.0 ± 9.1 0.24
Inpatient staysa 1.9 ± 2.2 2.0 ± 2.3 0.58
BDI 18.9 ± 10.1 21.2 ± 11.0 0.15
SCL-90-R global 1.2 ± 0.7 1.2 ± 0.6 0.75
SCL-90-R OC
subscale
1.9 ± 0.9 2.0 ± 0.8 0.38
GAF 41.6 ± 9.2 40.9 ± 10.2 0.60
SD, standard deviation; BDI, Beck Depression Inventory; SCL-90-R, Symptom
Checklist 90 revised; GAF, Global Assessment of Functioning; p, level of
significance for between-group comparison of included and excluded patients.
aThe number of previous inpatient stays.
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ments, in vivo EX/RP sessions accompanied by the
therapist, as well as self-directed exposure exercises.
All participants received two weekly 50-minute indi-
vidual therapy sessions and participated in group ther-
apies including a psychoeducative group, ergotherapy,
music therapy, and sport therapy. Mean treatment dur-
ation was 9 weeks (SD 3.5 weeks). On admission, 43
patients (58.9% of the sample) received psychotropic
medication. Thirty-seven patients (50.7%) received
SSRIs, namely escitalopram (12 patients), paroxetine
(12), citalopram (7), sertraline (4), fluoxetine (1), and
fluvoxamine (1). Thirteen participants (17.8%) received
antidepressants other than SSRIs, namely clomipramine
(6), mirtazapine (3), amitriptyline (3), reboxetine (1), and
venlafaxine (1). Thirteen patients received antipsychotics,
namely quetiapine (5), risperidone (3), pipamperone (2),
olanzapine (1), aripiprazol (1), chlorprothixen (1), flupen-
tixol (1), and sulpirid (1). Two patients received benzo-
diazepines, namely lorazepam and temazepam. Two
patients received opipramol. At discharge, 55 patients
(75%) were on medication. Forty-seven patients took
SSRIs, 18 took other antidepressants, and 13 received
antipsychotics. At follow-up, thirty-eight took SSRIs,
12 other antidepressants, and 8 antipsychotics. Within
the follow-up period, 95.4% of the participants under-
went outpatient treatment, and 14.1% reported having
been re-admitted to an inpatient setting.
Statistics
Means and standard deviations were computed for de-
scriptive purposes. t tests were calculated to compare
the participants’ QoL scores to data from a norm popu-
lation. Norm values are provided by Angermeyer et al.
[21] for a German sample of 2,050 individuals from the
general population. We conducted t tests for related
samples to examine changes over the course of treat-
ment. The level of significance was set at p < 0.05 (two-
tailed). Cohen’s d was calculated as the ratio of the mean
difference and the pooled standard deviation [26]. EffectTable 3 QoL and depressive symptoms at baseline and 1-yea
Norm OCD pre OCD f-up N
z
Psych. QoL 74.0 ± 15.7 44.1 ± 19.1 59.1 ± 21.6 −1.9
Phys. QoL 76.9 ± 17.7 56.6 ± 16.5 70.9 ± 19.2 −1.1
Soc. QoL 71.8 ± 18.5 54.1 ± 24.7 56.6 ± 22.7 −0.9
Env. QoL 70.4 ± 14.2 68.5 ± 15.9 74.4 ± 14.6 −0.1
Glob. QoL 67.6 ± 17.9 37.8 ± 21.5 59.2 ± 25.7 −1.6
BDI 18.9 ± 10.1 10.3 ± 10.1
QoL, quality of life; psych., psychological; phys., physical; soc., social; env., environm
months-follow-up; norm, sample (n = 2,050) from the German general population. z
score of the norm population divided by the SD of the norm population (compare
results are given in bold.sizes of 0.3 were considered small, 0.5 to 0.8 medium,
and >0.8 large [26]. We determined clinically significant
changes for individual participants according to the two-
fold criterion provided by Jacobson and Truax [27]. Test-
retest reliability for the subscales of the WHOQoL-BREF,
which is required to compute the reliable change index,
was derived from Skevington et al. [20]. To investigate
whether QoL changes are related to changes of depressive
symptoms, we conducted a linear regression analysis. We
computed difference scores (baseline minus follow-up) for
the change of WHOQoL-BREF scores and the BDI. The
change of WHOQoL-BREF was inserted as the dependent
variable, the change of BDI scores as the predictor.
Results
Quality of life at baseline
At baseline, the participants’ physical, psychological,
social, and global QoL was significantly diminished in
comparison to population norms. Data are presented
in Table 3. The impairment was most pronounced for
psychological QoL (nearly two standard deviations
below the norm). On the environmental subscale, the
participants’ QoL did not differ from the norm value
(p = 0.300).
Comparison of pre- and follow-up data
Quality of life
Social QoL did not significantly change from baseline to
follow-up. Global, physical, psychological, and environ-
mental QoL were significantly improved. Despite these
improvements, the participants’ QoL was still signifi-
cantly lower than the population norms at follow-up,
with the exception of the values of the environmental
subscale, which were significantly higher than those of
the population norm (p = 0.021). Data are presented in
Table 3 and Figure 2. Fifteen subjects (20.3%) showed
a clinically significant change in psychological QoL,
4 subjects (5.4%) in social QoL, 20 subjects (27%) in
physiological QoL, and 9 subjects in environmental QoL
(12.2%). Forty-nine participants (67.1%) did not showr follow-up for n = 73 patients with OCD
orm vs. pre Norm vs. f-up Baseline vs. f-up
p z p d p
<0.001 −0.94 <0.001 0.74 <0.001
5 <0.001 −0.34 0.010 0.80 <0.001
6 <0.001 −0.82 <0.001 0.11 0.316
3 0.300 0.28 0.021 0.39 <0.001
6 <0.001 −0.47 0.007 0.90 <0.001
0.85 <0.001
ental; glob., global; BDI, Beck Depression Inventory; pre, baseline; f-up, 12-
scores were computed as follows: mean score for OCD subjects minus mean

























baseline follow-up norm 
Figure 2 Quality of life at baseline and 12 months follow-up. QoL means as measured by the WHOQoL-BREF for patients with OCD at
baseline and 12 months follow-up (n = 73) and norm values from the German general population (n = 2,050). Higher values indicate better QoL.
Error bars represent standard errors.
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scales, and only one participant significantly improved
on all four domains.
Depressive symptoms
BDI scores significantly declined from 18.9 (SD 10.1) at
baseline to 9.6 (SD 8.8) at discharge (p < 0.001) and
remained stable at follow-up (please refer to Table 3 for a
comparison between baseline and follow-up scores). The
mean BDI scores at discharge and follow-up are below the
cutoff for depression.
Relation of quality of life and depressive symptoms
BDI pre-follow-up difference scores were highly cor-
related with difference scores for all QoL domains (all
p < 0.01). Linear regression analysis (Table 4) showed
that the change of BDI scores was a significant predictor
for the change of all QoL dimensions. The proportion
of explained variance was 57.3% for global QoL, 59.2%Table 4 Regression analyses predicting differences in
quality of life by differences in depression scores
R2 β t p
Predicting global QoL 0.573 −0.757 −9.758 <0.001
Predicting physical QoL 0.526 −0.726 −8.885 <0.001
Predicting psychological QoL 0.592 −0.770 −10.088 <0.001
Predicting social QoL 0.130 −0.360 −3.230 0.002
Predicting environmental QoL 0.197 −0.443 −4.167 <0.001
All variables were analyzed as difference scores, baseline minus follow-up.
Significant results are given in bold.for psychological QoL, 13% for social QoL, 19.7% for
environmental QoL, and 52.6% for physical QoL.
Discussion
The results from this study indicate the following: (1)
Compared to healthy subjects from the German general
population, the current sample of inpatients with OCD
suffered from a diminished global, physical, psychological,
and social QoL with baseline scores being one to two
standard deviations below norm values. Environmental
QoL was not impaired. (2) QoL was significantly improved
1 year after inpatient CBT with EX/RP and subsequent
outpatient treatment in all domains except social QoL.
Effect sizes were medium to large for global, physical,
and psychological QoL (Cohen’s d between 0.7 and 0.9).
However, only a small subgroup of the sample showed
clinically significant improvements. (3) Despite the im-
provements, participants’ global, physical, psychological,
and social QoL remained significantly lower than popula-
tion norms. (4) QoL improvements were predicted by a
reduction of depressive symptoms. The amelioration of
BDI scores was a good predictor of global, physical, and
psychological QoL improvements with the proportion of
the explained variance being greater than 50%. It is to note
that the present study has relevant limitations, most
prominently the lack of a severity measure of OCD and
the lack of standardized diagnostic interviews. Thus, the
presented results do not allow for directly investigating
the impact of alterations in OCD symptoms on changes in
QoL. The diagnoses were established by experienced
clinicians during the inpatient stay. However, we cannot
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biased the results.
Our results are in line with previous reports on signifi-
cantly reduced QoL in persons with OCD when com-
pared to norm values from the general population
[9,10,28]. The level of impairment observed in our study
corresponds well to data by Hollander et al. [10] and
Albert et al. [29] who reported that baseline scores were
at least one z score below norm values for each mental
health domain of the SF-36.
With regard to distinct QoL domains, reduced QoL in
the psychological domain and social functioning have
been reported based on different QoL measures [7,9,10].
Skevington and McCrate [30] recently published means
and standard deviations for the WHOQOL-BREF for dif-
ferent conditions. The score for psychological QoL of
our sample was lower than the scores of persons with
chronic schizophrenia, sleep disorders, diabetes mellitus,
and neurodegenerative disorders. Only persons with de-
pression reported a lower quality of life in the respective
domain.
The results concerning physical QoL are controversial:
Some studies found that physical QoL in persons with
OCD was not impaired [31], whereas others have
reported impairments [9]. One possible explanation is
that impaired physical QoL in persons with OCD might
reflect comorbid depressive symptoms. Moritz and
colleagues [9], who found that physical QoL was
impaired, reported that the criteria for major depression
or dysthymia were fulfilled by 37% of their participants.
In contrast, Koran et al. [31] used the same QoL meas-
ure (SF-36) and observed that physical QoL was com-
parable to norm values. Of note, in their sample only 2%
of the participants were diagnosed with major depres-
sion and 12% with dysthymia. The differences concer-
ning physical QoL cannot be attributed to age, as the
participants of the study by Moritz et al. were younger
than the sample by Koran et al. In our sample, physical
QoL was reduced at baseline, which might be driven by
the relatively high severity of comorbid depression
(mean baseline BDI 19). More specifically, it is to note
that the physical domain of the WHOQoL-BREF in-
cludes questions about the ability to manage daily
routines, working ability, sleep quality, and energy for
daily living. It seems plausibe that persons with mood
disorders according to ICD-10 criteria who suffer from
energy loss, diminished interest, and sleep disorders
score low on this domain.
Environmental QoL, which is covered by the WHOQOL-
BREF, but not by the SF-36, was not reduced in our sam-
ple and was slightly higher than in most other samples of
persons with OCD (e.g., Cordioli [13] who found a base-
line score which was more than 10 points lower than
ours). Interestingly, Stengler-Wenzke and colleagues [32],who analyzed a similar German OCD sample seeking help
at a University Medical Center (Leipzig), found a very
similar baseline score for environmental QoL. This might
be due to a selection bias. Patients with a stable socio-
economic background may be more likely to seek help in
a University Medical Center in an urban area. This line of
arguments fits well to the high level of education reported
in our sample. Only two participants did not finish school,
and 73% had at least a secondary level of education.
In line with other results, our findings indicate that
the QoL of persons with OCD can be improved in the
long run. In the randomized trial by Cordioli [13], the
QoL was found to be improved 3 months after cognitive
behavioral group therapy in comparison to baseline. This
observation comprised improvements on all four do-
mains of the WHOQOL-BREF with effect sizes within
the medium range (effect sizes were calculated by the
authors of the present paper based on means and stand-
ard deviations reported by Cordioli et al.).
Furthermore, we observed that the different QoL do-
mains improved to a different extent: Improvements were
most prominent for psychological and physical QoL,
whereas social QoL was not significantly changed. Other
studies with 12-month follow-up periods also found that
social QoL did not improve in persons with depression
aged 65 years or older [19] and in persons with social pho-
bia [18]. Possibly, profound changes concerning social
relationships and social support require prolonged periods
of time. Insufficient social support and impaired social
networks might be an etiological and maintaining factor
of various mental disorders rather than a consequence of
psychiatric symptoms.
Another important observation is that—despite signifi-
cant improvements—the QoL of persons with OCD
remained below population norms. This is in line with
other results [9].
With regard to potential mediators, we found that
QoL improvement was strongly linked to a reduction of
depressive symptoms. Previous studies indicated that
QoL and QoL improvement might be more strongly
associated with depression than with OCD severity
[9,16]. This implies that a careful diagnosis and, if ap-
plicable, treatment of comorbid depression is an import-
ant step in treating persons with OCD.
To the best of our knowledge, the present study is the
first that repeatedly administered a psychometrically
sound measure of QoL in persons with OCD over a
course of 12 months. Thus, our results extend previous
research by providing data on long-term changes of QoL
in persons with OCD. However, a number of significant
limitations need to be discussed. First, our study lacks a
control group. Second, we did not control for medica-
tion. Thus, conclusions about potential causal relation-
ships between the administration of inpatient CBT and
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and symptomatic changes cannot be drawn. We can
nevertheless draw on solid data demonstrating that
OCD is a chronic disorder which does not show con-
siderable improvement over time without treatment
[33,34]. Third, the current analysis is based on quality
management data from our clinic that, within the
period of observation, did not routinely include mea-
sures of OCD severity. For this reason, the baseline
scores of our sample were compared to data reported
in other studies in order to better characterize our sam-
ple. The baseline SCL-90-R global severity indices and
OC-subscale scores of our sample correspond well to
the scores of n = 43 persons with OCD reported by
Grabe et al. [35]. The baseline GAF score of 41.6 in our
sample indicates severe impairment and is considerably
lower than scores reported by Ramirez et al. [36] for
psychiatric outpatients belonging to several diagnostic
groups, including mood, anxiety, and eating disorders.
Another limitation is that structured interviews have
not been used. Future studies are needed to further dis-
entangle the impact of distinct changes in psychopath-
ology on long-term changes in the QoL. Furthermore,
it remains possible that we overestimated QoL im-
provements, as our study suffered from a considerable
amount of missing data. Patients who were less satisfied
with the treatment were possibly less likely to send
back the follow-up questionnaires. However, we showed
that the analyzed sample did not differ from the original
dataset concerning psychological distress and socio-
demographic data.
Conclusion
The present analysis shows that persons with OCD
suffer from low QoL which, in the current study,
improved over the course of 12 months. However, add-
itional research on the long-term effects of CBT on QoL
in the shape of a prospective, randomized, and con-
trolled clinical trial is warranted because the present
analysis has relevant limitations and does not allow for
conclusive statements. Despite significant increases, four
of five QoL domains remained diminished compared to
healthy people. Only a minority of our patients achieved
clinically significant long-term improvements of QoL.
The replication of a persistently compromised QoL after
state-of-the-art treatment would indicate the need for
the development of novel and more effective treatments
to improve the QoL in persons with OCD.
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